Clinical Study of Endostatin in Improving Radiation Pneumonia and Fibrosis

• Status: Unknown status
• Trial end date: 2020-07-31
• Target enrollment: 0
• Participant gender: All

Summary

To verify the efficacy and safety of endostatin in the treatment of SRILI（symptomatic radiation-induced lung injury） and fibrosis. The results of this study are expected to be a new clinical strategy for the treatment of radiation pneumonia and fibrosis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Xinqiao Hospital of Chongqing
• Treatments: Endostar protein; Endostatins

Criteria

Inclusion Criteria:

1. Patients defined as NSCLC who could not be operated on, phase III-IV;

2. EOCG PS: 0-3;

3. The clinical diagnosis is RILI, with grade 2-3;

4. No major organ dysfunction, such as heart failure and chronic obstructive pneumonia;

5. No Endostar use contraindication;

6. Volunteer to participate, good compliance, can cooperate with the test observation, and sign a written informed consent.

Exclusion Criteria:

1. Patient compliance is poor and violates the test regulations;

2. Major organ dysfunction like liver and kidney occurs, such as myocardial infarction, angina pectoris, liver transaminase increased significantly;

3. Hemorrhage or thrombus occurs, anticoagulant medication is required;

4. Serious adverse drug reactions occur during treatment;

5. The patient asked to be withdrawn from the trial;

6. Other antiangiogenic drugs were used.